TRexBio IPO Raises $116.7M for Immune Therapy

TRex Bio, Inc. has successfully priced its initial public offering, raising approximately $116.7 million before expenses. The clinical-stage biotechnology firm, concentrating on the therapeutic potential of tissue-resident regulatory T cells (Tregs) for autoimmune and inflammatory conditions, will debut on the Nasdaq Global Select Market under the ticker symbol TRXB. This significant capital infusion is set to fuel the advancement of its pipeline, which leverages a proprietary Deep Biology Platform designed to decode Treg functionality in human tissues.

The offering comprised 8,333,334 shares of common stock sold at $14.00 per share. An additional option for underwriters to purchase up to 1,250,000 shares at the same price has also been granted, potentially increasing the total proceeds. The successful completion of this IPO marks a pivotal moment for TRexBio, underscoring investor confidence in its novel approach to immunoregulatory medicine. The company's strategy centers on restoring immune balance and promoting tissue repair, addressing critical unmet needs in a patient population often underserved by current treatments.

The biotechnology sector, particularly companies focused on immunology and rare diseases, has seen robust investor interest. The market for autoimmune and inflammatory disease treatments is substantial, projected to reach hundreds of billions globally in the coming years, driven by an aging population and increasing disease prevalence. TRexBio's focus on Treg biology positions it within a highly innovative segment of this market, aiming to unlock new therapeutic modalities.

Leading the book-running management for this substantial offering were financial institutions including J.P. Morgan, Evercore ISI, Cantor, and Stifel. Wedbush PacGrow also served as a book-running manager. The company's shares are anticipated to commence trading on October 9, 2026, with the offering expected to finalize by October 13, 2026, contingent upon standard closing conditions. The U.S. Securities and Exchange Commission declared the company's registration statement effective on October 8, 2026.

TRexBio's innovative Deep Biology Platform is central to its drug discovery efforts. This platform provides deep insights into Treg behavior within human tissues, identifying key mechanisms of immune dysregulation and uncovering novel therapeutic targets. These insights are instrumental in guiding the development of TRexBio's wholly-owned pipeline candidates and informing its strategic collaborations with major pharmaceutical entities. The company is headquartered in South San Francisco, California, and is guided by an experienced leadership team.

The successful IPO provides TRexBio with crucial capital to advance its clinical programs and further validate its platform's potential. The company's focus on Treg biology represents a sophisticated approach to modulating the immune system, moving beyond broad immunosuppression to more targeted interventions. This strategy could offer significant advantages in terms of efficacy and safety for patients suffering from chronic autoimmune and inflammatory conditions.